|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Trandolapril#Adult Indications and Dosage]] |
| {{Trandolapril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==Dosage and Adminstration==
| |
| | |
| ====Hypertension====
| |
| The recommended initial dosage of MAVIK for patients not receiving a diuretic is 1 mg once daily in non-black patients and 2 mg in black patients. Dosage should be adjusted according to the blood pressure response. Generally, dosage adjustments should be made at intervals of at least 1 week. Most patients have required dosages of 2 to 4 mg once daily. There is little clinical experience with doses above 8 mg.
| |
| | |
| Patients inadequately treated with once-daily dosing at 4 mg may be treated with twice-daily dosing. If blood pressure is not adequately controlled with MAVIK monotherapy, a diuretic may be added.
| |
| | |
| In patients who are currently being treated with a [[diuretic]], symptomatic hypotension occasionally can occur following the initial dose of MAVIK. To reduce the likelihood of [[hypotension]], the diuretic should, if possible, be discontinued two to three days prior to beginning therapy with MAVIK. Then, if blood pressure is not controlled with MAVIK alone, [[diuretic therapy]] should be resumed. If the diuretic cannot be discontinued, an initial dose of 0.5 mg MAVIK should be used with careful medical supervision for several hours until blood pressure has stabilized. The dosage should subsequently be titrated (as described above) to the optimal response.
| |
| Concomitant administration of MAVIK with potassium supplements, potassium salt substitutes, or potassium sparing diuretics can lead to increases of serum potassium.
| |
| | |
| ====Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction====
| |
| The recommended starting dose is 1 mg, once daily. Following the initial dose, all patients should be titrated (as tolerated) toward a target dose of 4 mg, once daily. If a 4 mg dose is not tolerated, patients can continue therapy with the greatest tolerated dose.
| |
| | |
| ====Dosage Adjustment in Renal Impairment or Hepatic Cirrhosis====
| |
| For patients with a [[creatinine clearance]] < 30 mL/min. or with hepatic cirrhosis, the recommended starting dose, based on clinical and pharmacokinetic data, is 0.5 mg daily. Patients should subsequently have their dosage titrated (as described above) to the optimal response.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MAVIK (TRANDOLAPRIL) TABLET [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5ad67ea2-409c-4f52-a9b8-38216209609a | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |